Cel-Sci Corporation is a biotechnology company focused on the development of innovative immunotherapy products for the treatment of cancer and other life-threatening diseases
The company is primarily engaged in the research and development of its lead product candidate, which leverages the unique properties of the immune system to combat tumors. With a commitment to enhancing patient outcomes, Cel-Sci explores novel therapeutic approaches and collaborates with research institutions to advance its clinical programs, aiming to bring new hope to patients in need of effective treatment options.
CEL-SCI shares are trading higher by 18.6% during Wednesday's session. The company received positive feedback from the FDA regarding their cancer immunotherapy.
Shares of U Power Limited (NASDAQUCAR) shares moved lower during Monday’s session after the company announced pricing of registered follow-on offering of 10 million units at a purchase price of $1.20 per unit.
CEL-SCI Corporation (AMEX: CVM) announced that the British National Institute for Health and Care Excellence (NICE) has selected Multikine (Leukocyte Interleukin, Injection) to be evaluated as the potential new standard of care for squamous cell carcinoma of the head and neck
